arrow
T

Teresa Bernal

instituto de investigacion sanitaria del principado de asturias
H指数:34
被引数:7,039

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy

可测量残留病灶评估作为急性髓系白血病治疗早期疗效终点:一项多国PETHEMA研究,纳入2623例接受强化疗的患者

Leukemia
IF13.4
2026-10-080
PRE
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry

维奈克拉为基础的治疗与单用去甲基化药物在初诊急性髓系白血病不适宜患者中的比较:一项来自PETHEMA登记研究的真实世界研究

Leukemia
IF13.4
2026-10-060
OA
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial

Quizartinib与FLAG-IDA联合治疗复发或难治性急性髓系白血病(FLAG-QUIDA):一项PETHEMA I-II期临床试验

2026-06-290
OAAI
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group

急性髓系白血病患者在首次缓解期接受 allo 移植时分子分型的临床影响:PETHEMA 小组的研究

2026-05-070
PRE
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Celleoplasm: A PETHEMA Study

血液病性浆细胞样树突状细胞肿瘤的医疗资源利用和治疗成本:一项PETHEMA研究

Cancers
IF4.4
2026-03-030
OAAI
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry
2026-01-080
PRE
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

自体干细胞移植与强化疗巩固治疗急性髓系白血病患者的长期获益:一项来自PETHEMA AML登记研究的倾向性评分匹配分析

Leukemia
IF13.4
2025-09-010
OAAI
APPLICATION OF OPTICAL GENOME MAPPING IN MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE

光学基因组图谱在正常核型骨髓增生异常综合征中的应用

2025-09-010
PRE
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

他米巴罗替与阿扎胞苷联合治疗新诊断高危骨髓增生异常综合征(MDS)的SELECT-MDS-1三期研究的关键结果

2025-05-090
OAAI
Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes

伴有环状铁粒幼细胞的骨髓增生异常肿瘤在成人中:先天性铁粒幼细胞贫血基因中胚系变异的富集

LEUKEMIA
IF13.4
2025-05-070
PRE
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

自体或异基因造血干细胞移植作为成人继发性急性髓系白血病患者的首线治疗:PETHEMA登记研究经验

2025-02-010
PRE
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX
CANCER
IF5.1
2024-10-300
OAAI
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3trial
2024-09-011
PRE
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
2024-08-080
OAAI
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

del(5q) 骨髓增生异常肿瘤患者停用来那度胺后的输血独立性: HARMONY Alliance研究

LEUKEMIA
IF13.4
2024-08-050
OA
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
2024-06-170
PRE
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI